FDA Approves First Muscle-Targeted Therapy for Spinal Muscular Atrophy — What It Means for Neuromuscular Medicine
Published: September 13, 2026 | Category: Drug Approval
On September 11, 2026, the FDA approved Isembyld (apitegromab-mstn) — the first and only therapy designed to directly target muscle tissue in spinal muscular atrophy (SMA). Developed by Scholar Rock, it represents a fundamentally different approach to a disease that has, until now, been managed almost entirely through therapies targeting the motor neuron.
Why This Is Different
Every FDA-approved SMA therapy to date — Spinraza, Zolgensma, Evrysdi — works through SMN2 upregulation: increasing production of the survival motor neuron protein that SMA patients cannot produce in adequate amounts due to a genetic defect. These therapies target the neurological root cause.
Isembyld targets something else entirely: muscle itself.
Apitegromab is a monoclonal antibody that inhibits myostatin — a protein that normally signals muscles to stop growing. By blocking myostatin, the drug removes a brake on muscle growth and regeneration. The concept has been validated in preclinical models for decades; Isembyld is the first to demonstrate it works in humans with SMA.
Who It’s For
The approval is narrow: patients 2 years and older with SMA who are already receiving an SMN2-targeted treatment (which covers the vast majority of treated SMA patients). The drug is given as a monthly IV infusion.
This is an add-on therapy, not a replacement. Patients currently on Spinraza, Zolgensma, or Evrysdi do not stop those treatments.
The SAPPHIRE Trial
Approval was based primarily on the Phase 3 SAPPHIRE trial, which showed clinically meaningful improvements in motor function compared to sham in patients with Type 2 and Type 3 SMA. Earlier Phase 2 studies (TOPAZ and ONYX) supported the mechanism and dose rationale.
Why This Matters Beyond SMA
Myostatin inhibition is one of the most sought-after mechanisms in all of medicine. The same pathway — myostatin acting as a brake on muscle growth — is relevant to:
– Sarcopenia (age-related muscle loss)
– Muscle wasting in cancer, COPD, and other chronic diseases
– GLP-1–associated muscle loss — one of the most common concerns I hear from patients on semaglutide and tirzepatide is the loss of lean body mass alongside fat. Any drug that helps preserve or build muscle while patients are losing weight could be transformative for obesity medicine.
Research into myostatin pathway therapies for obesity and sarcopenia is ongoing. Isembyld’s approval is the first proof that this mechanism works in humans — a significant translational milestone.
Bottom Line
For the SMA community, this approval is a milestone: a first-in-class muscle-targeted therapy that works alongside existing SMN-targeted treatments. For the broader medical community — and for physicians managing patients on weight loss medications — Isembyld is a proof of concept worth watching. Muscle-targeted therapies are coming. Their first clinical foothold just happened.
Dr. Ethan Lazarus, MD, DABOM, DABFM, MFOMA | Clinical Nutrition Center, Greenwood Village, CO